Benchmarking biomarker-based criteria for Alzheimer's disease: Data from the Swedish Dementia Registry, SveDem

Alzheimer's and Dementia

Volumn 11, Issue 12, 2015, Pages 1470-1479

  Rosén, Christoffer ^a   Farahmand, Bahman ^b,c   Skillbäck, Tobias ^a   Nägga, Katarina ^d   Mattsson, Niklas ^a,e   Kilander, Lena ^f   Religa, Dorota ^b,c   Wimo, Anders ^b   Blennow, Kaj ^a   Winblad, Bengt ^b,c   Zetterberg, Henrik ^a,g   Eriksdotter, Maria ^b,c  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d LUND UNIVERSITY   (Sweden)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UPPSALA UNIVERSITY   (Sweden)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Alzheimer's disease; Biomarkers; Cerebrospinal fluid; Diagnosis; Diagnostic criteria

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; PHOSPHOPROTEIN; TAU PROTEIN; AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; PEPTIDE FRAGMENT;

ADULT; AGE DISTRIBUTION; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; FEMALE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; PRIORITY JOURNAL; SWEDEN; BENCHMARKING; MIDDLE AGED; PHOSPHORYLATION; PROCEDURES; REGISTER; SEX DIFFERENCE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BENCHMARKING; BIOMARKERS; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PHOSPHORYLATION; REGISTRIES; SEX FACTORS; SWEDEN; TAU PROTEINS;

EID: 84949827682     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2015.04.007     Document Type: Article

References (45)

1. World Health Organization The ICD-10 classification of mental and behavioural disorders: Diagnostic criteria for research 1993 World Health Organization Geneva
2. G. McKhann, D. Drachman, M. Folstein, R. Katzman, D. Price, and E.M. Stadlan Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease Neurology 34 1984 939 944
3. K. Blennow, M.J. de Leon, and H. Zetterberg Alzheimer's disease Lancet 368 2006 387 403
4. C. Rosen, O. Hansson, K. Blennow, and H. Zetterberg Fluid biomarkers in Alzheimer's disease - current concepts Mol Neurodegener 8 2013 20
5. B. Dubois, H.H. Feldman, C. Jacova, S.T. Dekosky, P. Barberger-Gateau, J. Cummings, and et al. Research criteria for the diagnosis of Alzheimer's disease: Revising the NINCDS-ADRDA criteria Lancet Neurol 6 2007 734 746
6. G.M. McKhann, D.S. Knopman, H. Chertkow, B.T. Hyman, C.R. Jack Jr., C.H. Kawas, and et al. The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement 7 2011 263 269
7. M.S. Albert, S.T. DeKosky, D. Dickson, B. Dubois, H.H. Feldman, N.C. Fox, and et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement 7 2011 270 279
8. R.A. Sperling, P.S. Aisen, L.A. Beckett, D.A. Bennett, S. Craft, A.M. Fagan, and et al. Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement 7 2011 280 292
9. F.H. Duits, N.D. Prins, A.W. Lemstra, Y.A. Pijnenburg, F.H. Bouwman, C.E. Teunissen, and et al. Diagnostic impact of CSF biomarkers for Alzheimer's disease in a tertiary memory clinic Alzheimers Dement 11 2015 523 532
10. B. Dubois, H.H. Feldman, C. Jacova, H. Hampel, J.L. Molinuevo, K. Blennow, and et al. Advancing research diagnostic criteria for Alzheimer's disease: The IWG-2 criteria Lancet Neurol 13 2014 614 629
11. SveDem About SveDem, Swedish Dementia Registry 2014 Uppsala Clinical Research Center Uppsala http://www.ucr.uu.se/svedem/index.php/about-svedem Accessed November 19, 2014
12. D. Campion, C. Dumanchin, D. Hannequin, B. Dubois, S. Belliard, M. Puel, and et al. Early-onset autosomal dominant Alzheimer disease: Prevalence, genetic heterogeneity, and mutation spectrum Am J Hum Genet 65 1999 664 670
13. A. Wimo, D. Religa, K. Spangberg, A.K. Edlund, B. Winblad, and M. Eriksdotter Costs of diagnosing dementia: Results from SveDem, the Swedish Dementia Registry Int J Geriatr Psychiatry 28 2013 1039 1044
14. D. Religa, K. Spangberg, A. Wimo, A.K. Edlund, B. Winblad, and M. Eriksdotter-Jonhagen Dementia diagnosis differs in men and women and depends on age and dementia severity: Data from SveDem, the Swedish Dementia Quality Registry Dement Geriatr Cogn Disord 33 2012 90 95
15. N. Mattsson, E. Portelius, S. Rolstad, M. Gustavsson, U. Andreasson, M. Stridsberg, and et al. Longitudinal cerebrospinal fluid biomarkers over four years in mild cognitive impairment J Alzheimers Dis 30 2012 767 778
16. J.B. Toledo, S.X. Xie, J.Q. Trojanowski, and L.M. Shaw Longitudinal change in CSF tau and Abeta biomarkers for up to 48 months in ADNI Acta Neuropathol 126 2013 659 670
17. K. Blennow, A. Wallin, H. Agren, C. Spenger, J. Siegfried, and E. Vanmechelen Tau protein in cerebrospinal fluid: A biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol 26 1995 231 245
18. E. Vanmechelen, H. Vanderstichele, P. Davidsson, E. Van Kerschaver, B. Van Der Perre, M. Sjogren, and et al. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: A sandwich ELISA with a synthetic phosphopeptide for standardization Neurosci Lett 285 2000 49 52
19. N. Andreasen, C. Hesse, P. Davidsson, L. Minthon, A. Wallin, B. Winblad, and et al. Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: Differences between early- and late-onset Alzheimer disease and stability during the course of disease Arch Neurol 56 1999 673 680
20. S. Palmqvist, H. Zetterberg, K. Blennow, S. Vestberg, U. Andreasson, D.J. Brooks, and et al. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid beta-amyloid 42: A cross-validation study against amyloid positron emission tomography JAMA Neurol 71 2014 1282 1289
21. O. Hansson, H. Zetterberg, P. Buchhave, E. Londos, K. Blennow, and L. Minthon Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: A follow-up study Lancet Neurol 5 2006 228 234
22. K.P. Burnham, D.R. Anderson, and K.P. Burnham Model selection and multimodel inference a practical information-theoretic approach 2nd ed. 2002 Springer New York p. xxvi, 488 p
23. D.S. Knopman, S.T. DeKosky, J.L. Cummings, H. Chui, J. Corey-Bloom, N. Relkin, and et al. Practice parameter: Diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology Neurology 56 2001 1143 1153
24. T.G. Beach, S.E. Monsell, L.E. Phillips, and W. Kukull Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010 J Neuropathol Exp Neurol 71 2012 266 273
25. S. Salloway, R. Sperling, N.C. Fox, K. Blennow, W. Klunk, M. Raskind, and et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease N Engl J Med 370 2014 322 333
26. S. Engelborghs, K. De Vreese, T. Van de Casteele, H. Vanderstichele, B. Van Everbroeck, P. Cras, and et al. Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia Neurobiol Aging 29 2008 1143 1159
27. L.M. Shaw, H. Vanderstichele, M. Knapik-Czajka, C.M. Clark, P.S. Aisen, R.C. Petersen, and et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects Ann Neurol 65 2009 403 413
28. H. Struyfs, J.L. Molinuevo, J.J. Martin, P.P. De Deyn, and S. Engelborghs Validation of the AD-CSF-index in autopsy-confirmed Alzheimer's disease patients and healthy controls J Alzheimers Dis 41 2014 903 909
29. T. Tapiola, I. Alafuzoff, S.K. Herukka, L. Parkkinen, P. Hartikainen, H. Soininen, and et al. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain Arch Neurol 66 2009 382 389
30. N. Le Bastard, J.J. Martin, E. Vanmechelen, H. Vanderstichele, P.P. De Deyn, and S. Engelborghs Added diagnostic value of CSF biomarkers in differential dementia diagnosis Neurobiol Aging 31 2010 1867 1876
31. N. Mattsson, P.S. Insel, S. Landau, W. Jagust, M. Donohue, L.M. Shaw, and et al. Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease Ann Clin Transl Neurol 1 2014 534 543
32. F. Falahati, S.M. Fereshtehnejad, D. Religa, L.O. Wahlund, E. Westman, and M. Eriksdotter The use of MRI, CT and lumbar puncture in dementia diagnostics: Data from the SveDem Registry Dement Geriatr Cogn Disord 39 2014 81 91
33. N. Mattsson, U. Andreasson, S. Persson, H. Arai, S.D. Batish, S. Bernardini, and et al. The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers Alzheimers Dement 7 2011 386 395 e6
34. M. del Campo, B. Mollenhauer, A. Bertolotto, S. Engelborghs, H. Hampel, A.H. Simonsen, and et al. Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: An update Biomark Med 6 2012 419 430
35. M.C. Carrillo, K. Blennow, H. Soares, P. Lewczuk, N. Mattsson, P. Oberoi, and et al. Global standardization measurement of cerebral spinal fluid for Alzheimer's disease: An update from the Alzheimer's Association Global Biomarkers Consortium Alzheimers Dement 9 2013 137 140
36. A.R. Oksengard, L. Cavallin, R. Axelsson, C. Andersson, K. Nagga, B. Winblad, and et al. Lack of accuracy for the proposed 'Dubois criteria' in Alzheimer's disease: A validation study from the Swedish brain power initiative Dement Geriatr Cogn Disord 30 2010 374 380
37. F.H. Bouwman, N.S. Schoonenboom, N.A. Verwey, E.J. van Elk, A. Kok, M.A. Blankenstein, and et al. CSF biomarker levels in early and late onset Alzheimer's disease Neurobiol Aging 30 2009 1895 1901
38. B.L. Plassman, K.M. Langa, G.G. Fisher, S.G. Heeringa, D.R. Weir, M.B. Ofstedal, and et al. Prevalence of dementia in the United States: The aging, demographics, and memory study Neuroepidemiology 29 2007 125 132
39. M.I. Kester, A.E. van der Vlies, M.A. Blankenstein, Y.A. Pijnenburg, E.J. van Elk, P. Scheltens, and et al. CSF biomarkers predict rate of cognitive decline in Alzheimer disease Neurology 73 2009 1353 1358
40. T.T. Seppala, A.M. Koivisto, P. Hartikainen, S. Helisalmi, H. Soininen, and S.K. Herukka Longitudinal changes of CSF biomarkers in Alzheimer's disease J Alzheimers Dis 25 2011 583 594
41. M. Degerman Gunnarsson, L. Lannfelt, M. Ingelsson, H. Basun, and L. Kilander High tau levels in cerebrospinal fluid predict rapid decline and increased dementia mortality in Alzheimer's disease Dement Geriatr Cogn Disord 37 2014 196 206
42. K. Samgard, H. Zetterberg, K. Blennow, O. Hansson, L. Minthon, and E. Londos Cerebrospinal fluid total tau as a marker of Alzheimer's disease intensity Int J Geriatr Psychiatry 25 2010 403 410
43. J. Dumurgier, F. Mouton-Liger, P. Lapalus, M. Prevot, J.L. Laplanche, J. Hugon, and et al. Cerebrospinal fluid PKR level predicts cognitive decline in Alzheimer's disease PLoS One 8 2013 e53587
44. C. Rosen, C.H. Andersson, U. Andreasson, J.L. Molinuevo, M. Bjerke, L. Rami, and et al. Increased levels of chitotriosidase and YKL-40 in cerebrospinal fluid from patients with Alzheimer's disease Dement Geriatr Cogn Dis Extra 4 2014 297 304
45. N. Mattsson, H. Zetterberg, O. Hansson, N. Andreasen, L. Parnetti, M. Jonsson, and et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment JAMA 302 2009 385 393